VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Manhattan Associates, Inc. vs Sanofi
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Manhattan Associates, Inc.
MANH · The Nasdaq Stock Market LLC
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Manhattan Associates, Inc.'s moat claims, evidence, and risks.
View MANH analysisSanofi
SAN · Euronext Paris
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Comparison highlights
- Moat score gap: Sanofi leads (74 / 100 vs 56 / 100 for Manhattan Associates, Inc.).
- Segment focus: Manhattan Associates, Inc. has 4 segments (50.4% in Professional services (implementation, consulting, training)); Sanofi has 3 segments (79.8% in Pharma (Prescription Medicines)).
- Primary market structure: Competitive vs Oligopoly. Pricing power: Weak vs Moderate.
- Moat breadth: Manhattan Associates, Inc. has 7 moat types across 1 domains; Sanofi has 5 across 3.
Primary market context
Manhattan Associates, Inc.
Professional services (implementation, consulting, training)
Supply chain & omnichannel software implementation and consulting services
Global
Enterprises implementing or expanding supply chain/omnichannel systems
Implementation and advisory services provider
50.4%
Sanofi
Pharma (Prescription Medicines)
Branded prescription pharmaceuticals (immunology, rare disease, neurology, oncology, general medicines)
Global
Patients via payers/providers and channel partners (wholesalers, pharmacies, hospitals)
Research-based drug developer, manufacturer, and marketer
79.8%
Side-by-side metrics
Moat coverage
Shared moat types
No overlap yet.
Manhattan Associates, Inc. strengths
Sanofi strengths
Segment mix
Manhattan Associates, Inc. segments
Full profile >Cloud subscriptions (Manhattan Active SaaS)
Oligopoly
Professional services (implementation, consulting, training)
Competitive
Maintenance and support (legacy perpetual licenses)
Monopoly
Perpetual licenses and hardware
Competitive
Sanofi segments
Full profile >Pharma (Prescription Medicines)
Oligopoly
Vaccines
Oligopoly
Opella (Consumer Healthcare - Sanofi minority stake)
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.